US SEC Trading Suspension Halt Orders — July 30, 2026

Implemented a 1-for-22 reverse stock split on July 16, 2026, to meet the $1.00 bid price requirement, but the stock must now maintain a closing bid above $1.00 through December 7, 2026, or face immediate suspension under new Nasdaq rules

Regained compliance with Nasdaq's Bid Price Rule on July 24, 2026, but is under a one-year Discretionary Panel Monitor with no second chances—any future deficiency triggers an automatic delisting hearing

Received a Nasdaq deficiency notice on July 24, 2026, with a 180-day cure period; the stock continues trading but faces delisting risk if it cannot sustain a $1.00 closing bid for 10 consecutive days

Received an NYSE deficiency notice on July 24, 2026, with a six-month cure period; management is considering a reverse stock split but has not committed, creating uncertainty

Nasdaq amended its listing rules on July 22, 2026, to allow immediate suspension for failure to meet the $5 million market value of listed securities requirement, adding a second, more immediate delisting risk beyond the bid price

The Discretionary Panel Monitor prohibits Curis from submitting a compliance plan or receiving Staff-granted extensions for any future deficiency, making it the most fragile of the four companies post-compliance

The company also has a 7.875% Series A Cumulative Redeemable Preferred Stock (LFTPrA) listed on the NYSE, which could be affected if the common stock is delisted, creating a potential cascading risk for preferred holders

The Nasdaq Hearings Panel granted an exception on July 29, 2026, but will maintain jurisdiction until December 7, 2026, meaning the company is under continuous regulatory surveillance with no room for error

New Nasdaq rule (July 22, 2026) allows immediate suspension if market value of listed securities falls below $5 million, creating a second, more severe risk beyond the bid price deficiency

The one-year Discretionary Panel Monitor means any future non-compliance results in an automatic delisting hearing with no opportunity for a compliance plan or Staff extension

The company has 180 days to achieve a $1.00 closing bid for 10 consecutive days; failure could lead to delisting from Nasdaq Capital Market

The six-month cure period is standard, but management's lack of commitment to a reverse split or other remedy introduces execution risk

The 1-for-22 reverse split is highly dilutive to existing shareholders and may not be sufficient to maintain compliance if the stock price falls again

The clustering of four deficiency notices in one week suggests a broader market trend of low-priced stocks failing to meet exchange requirements, potentially signaling a liquidity crisis in the micro-cap sector

The company must maintain a $1.00 bid price every trading day until December 7, 2026—only 130 days—leaving no room for price volatility

Unlike Flux Power or Lument, Curis has no cure period for future deficiencies; any slip-up triggers immediate delisting proceedings

Having regained compliance, Curis may attract buyers seeking a 'clean' listing status, but the one-year monitor limits upside as any misstep triggers delisting

The 180-day compliance period provides a catalyst for management to take corrective actions (e.g., reverse split, buyback, or operational improvements), which could create short-term trading opportunities

The 7.875% Series A Preferred (LFTPrA) may offer a yield opportunity if the common stock regains compliance, but delisting risk for the common could impair the preferred's liquidity

The 1-for-22 reverse split may create a temporary price floor near $1.00, but the new Nasdaq market value rule adds a second, less visible risk that could trigger a sudden suspension

The six-month window provides time for management to execute a reverse split or other remedy; if successful, the stock could re-rate as the delisting risk is removed

If Flux Power meets the market value of publicly held shares requirement, it could qualify for a second 180-day period, effectively giving it a full year to regain compliance

Four companies received or resolved deficiency notices in a single week (July 24-29, 2026), indicating a systemic wave of non-compliance among small-cap stocks with sub-$1.00 bid prices, likely driven by broader market weakness or sector-specific headwinds

Nasdaq offers a 180-day initial cure period (with a potential 180-day extension for Flux Power), while NYSE provides a six-month cure period (Lument Finance Trust), giving NYSE-listed companies slightly more time but similar outcomes

Nasdaq's July 22, 2026 rule change allowing immediate suspension for failure to meet the $5 million market value of listed securities requirement (impacting Genprex) signals a stricter enforcement environment, increasing delisting risk for micro-cap issuers

Both Genprex (1-for-22) and Lument (considering) are using or contemplating reverse stock splits to address bid price deficiencies, a common but often ineffective tactic that can lead to further price declines post-split

Curis's one-year monitor with zero tolerance for future deficiencies may become a standard outcome for companies that narrowly avoid delisting, creating a new class of 'zombie' listings with no margin for error

Lument's 7.875% Series A Preferred (LFTPrA) is listed on the NYSE alongside the common stock (LFT), meaning a delisting of the common could impair the preferred's liquidity and price, highlighting cross-security risks in distressed situations

Must maintain $1.00 bid price through December 7, 2026; watch for any price dips below $1.00 that could trigger immediate suspension under new Nasdaq rules

Under one-year Discretionary Panel Monitor until July 24, 2027; any future deficiency will trigger automatic delisting hearing—monitor for any operational or financial setbacks

180-day compliance period ends ~January 20, 2027; watch for management announcements regarding reverse splits, buybacks, or other corrective actions

Six-month cure period ends ~January 24, 2027; watch for shareholder vote on reverse split or other remedy, and monitor preferred stock (LFTPrA) for contagion effects

Monitor other micro-cap stocks with market values near $5 million for potential suspension under the new July 22, 2026 rule

Watch for additional 8-K filings from other micro-cap companies receiving deficiency notices in the coming weeks, which could signal a broader market trend

Reverse split effective July 16, 2026; monitor post-split price action for stability or further decline, which would increase delisting risk